Biophytis Stock Is Trading Higher On Encouraging Preclinical Data From COVID-19 Study With Sarconeos

• Biophytis SA (NASDAQ: BPTS) announced new positive preclinical data on Sarconeos (BIO101) in hamsters infected with SARS-CoV-2, the virus responsible for COVID-19.

• The data will be presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).

• The study revealed that Sarconeos (BIO101) daily treatment prevented respiratory function deterioration in SARS-CoV-2-infected mammals and provided preclinical proof of concept for the ongoing Phase 2/3 COVA study.

• The second interim analysis from COVA Phase 2/3 study is anticipated in 3Q of 2021.

• The results showed that at five dpi, a classical measure of respiratory distress significantly increased in the group treated with the vehicle.

• In animals treated with Sarconeos, the value was significantly reduced compared to vehicle-treated infected animals (0.35 ± 0.02).

• End Expiratory Pause (EEP) is proportional to the degree of obstruction of the lower airways. In Sarconeos (BIO101)-treated animals. The daily administration of BIO101 for five days remarkably restored the EEP time of the treated animals to a comparable level of uninfected control animals.

• Price Action: BPTS shares are up 17.2% at $10.59 during the market session on the last check Monday.

See more from Benzinga

• Click here for options trades from Benzinga

• Allena Revises Interim Reloxaliase Analysis Targeted Now For Q1 2022; ALLN-346 Phase 2 Data On Track For End Of 2021

• Cellectar, LegoChemBio Team Up To Develop Phospholipid Drug Conjugates For Solid Tumors

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.